Product Description

🔹 Product Overview
Dacihal 0.5 mg Vial contains Dactinomycin 0.5 mg, also known as Actinomycin D, an antineoplastic antibiotic used as part of chemotherapy protocols for several types of cancer. Dactinomycin works by interfering with DNA-dependent RNA synthesis, thereby inhibiting the growth and multiplication of cancer cells.
Dacihal is administered intravenously by qualified healthcare professionals under specialist oncology supervision.

🔹 Composition
Active Ingredient: Dactinomycin
Strength: 0.5 mg
Presentation: 0.5 mg/vial
Dosage Form: Lyophilized powder for injection
Route: Intravenous use
Therapeutic Class: Antineoplastic antibiotic / Cytotoxic chemotherapy agent

🔹 Uses And Indications
Dacihal may be included in chemotherapy protocols for:
Wilms' tumor
Rhabdomyosarcoma
Ewing sarcoma
Testicular cancer
Gestational trophoblastic neoplasia
Selected other solid tumors according to established oncology protocols

The specific indication and chemotherapy regimen depend on the type, stage and characteristics of the cancer and the treating oncologist's protocol.

🔹 How It Works
Dactinomycin binds to DNA, interfering with DNA-dependent RNA synthesis and preventing cancer cells from producing essential proteins. This inhibits cancer-cell growth and multiplication and contributes to cancer-cell death.

🔹 Key Benefits
Provides antineoplastic activity as part of established chemotherapy protocols.
Used in the treatment of several pediatric and adult malignancies.
Can be combined with other anticancer medicines depending on the treatment protocol.
Available as a 0.5 mg lyophilized injectable vial.

🔹 Dosage And Administration
Dacihal 0.5 mg Vial must be administered only by qualified healthcare professionals.
The dose and treatment schedule are individualized according to the patient's cancer type, treatment protocol, body size, blood counts, liver function and overall clinical condition.
The medicine is prepared and administered by the healthcare team through the intravenous route. It should not be self-administered.

🔹 Possible Side Effects
Dactinomycin may cause:
Nausea and vomiting
Loss of appetite
Mouth ulcers or mucositis
Diarrhea
Low blood-cell counts
Low platelet count
Fatigue
Liver abnormalities
Skin reactions
Hair loss
Serious adverse effects can include severe bone-marrow suppression, liver injury and tissue damage if the medicine accidentally leaks outside the vein.

🔹 Precautions And Warnings
Use only under specialist oncology supervision.
Regular blood counts should be performed during treatment because dactinomycin can cause significant bone-marrow suppression.
Liver and kidney function may require monitoring.
Inform the doctor about existing liver or kidney disease.
Report unusual bleeding, bruising, fever, severe mouth sores or signs of infection promptly.
Care should be taken during administration because extravasation can cause significant local tissue injury.
Live vaccines should generally be avoided during significant immunosuppression unless specifically advised by the treating physician.
Dactinomycin can cause fetal harm; pregnancy should be avoided during treatment and appropriate contraception should be discussed with the oncology team.
Inform the doctor about all medicines and cancer treatments being received, including radiotherapy.

🔹 Storage
Store Dacihal 0.5 mg Vial below 30°C according to the manufacturer's labeled storage conditions. Keep the vial protected from excessive heat and light and maintain appropriate pharmaceutical storage conditions.